Salute e Benessere

Clario delivers substantial gains toward diversity and net-zero emission goals…

Notable highlights from the report include: Notable highlights from the report include: "We firmly believe in the power of diversity as a driving force behind our continuous improvement in performance and innovation," saidDavid Fusco, Chief Human Capital Officer at Clario. "It is also behind our success in delivering on our environmental and governance commitments. For us, we see diversity and inclusion as a means to enhance our ability to serve our customers better and drive…
PR Newswire
11/12/2023

Cancer Biopsy Market Surpass $67.11 billion by 2030 - Exclusive Report by…

Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/5930 Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/5930 Additionally, technological advancements in biopsy techniques are further driving market growth. The development of minimally invasive biopsy procedures, such as liquid biopsy and image-guided biopsy, has improved the accuracy and precision of cancer diagnosis. These advanced...
PR Newswire
11/12/2023

North America Artificial Intelligence in Healthcare Market to hit USD 114.2…

The widespread integration of electronic health records (EHRs) has generated vast and intricate datasets within the healthcare system. In North America, the key driver for the adoption of artificial intelligence (AI) in healthcare lies in the potential to leverage AI technologies for the efficient analysis of these extensive datasets. AI applications can play a pivotal role in transforming healthcare by extracting meaningful insights from EHRs. The widespread integration of electronic health...
PR Newswire
11/12/2023

Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle…

Dr. Maki has two decades of experience in the biotech and pharma industry, with a track record of successful deals and partnerships across multiple therapeutic areas and modalities including significant numbers in antibody therapeutics. Most recently, she served as Senior Vice President and Head of Business Development at ReCode Therapeutics, where she led business development, corporate development, investor and public relations. At ReCode Therapeutics, she was part of the team that raised a…
PR Newswire
11/12/2023

EQ Europe: Successful leaders prioritize mental health to enhance workplace…

Date: Feb 1st Date: Feb 1st Location: Stockholm, Artillerigatan 6 or online. Time:Coffee and sandwiches will be served from07.30 am. The seminar is between08.00-9.00 am. Registration: Name and email toinfo@eqeurope.com. RSVP byJanuary 24th. EQ Europe´sCorporate Mental Health Program has proven that EQ-skilled leaders and organizations can make a profound impact by raising awareness, de-stigmatizing, and fostering a culture of trust, empathy, and belonging...
PR Newswire
11/12/2023

Hematology Diagnostics Market to Reach $16.87 Billion, Globally, by 2032 at 4.4%…

Request Sample of the Report on Hematology Diagnostics Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/11356 Request Sample of the Report on Hematology Diagnostics Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/11356 Prime determinants of growth The global hematology diagnostics market is experiencing rapid growth owing to the significant rise in the number of chronic diseases around the world. Diseases such as anemia,...
PR Newswire
11/12/2023

SkylineDx and VIB Initiate Joint Research Program on Immune Prediction

POINTILLISM 2.0 is a collaborative effort that reflects its interdisciplinary nature by bringing together research and tech transfer groups from VIB, KU Leuven and Skyline Dx, as well as oncologists, surgeons, pathologists from the University Hospital (UZ) Leuven, to work in synergy. The project benefits from the expertise of VIB-KU Leuven's Center for Cancer Biology (CCB), which is renowned for its work in studying the tumor microenvironment and the molecular and cellular mechanisms of cancer…
PR Newswire
11/12/2023

Blood Screening Market is Expected to Reach $ 4.9 billion, by 2032 at 7.5% CAGR…

Request Sample of the Report on Blood Screening Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/2826 Request Sample of the Report on Blood Screening Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/2826 Prime determinants of growth The blood screening market has experienced significant rise in demand for donated blood for medical applications, and surge in number of blood donations globally. Report coverage & details:...
PR Newswire
11/12/2023

Hoba Therapeutics raises EUR 23 million in a Series A to advance new drug…

Neuropathic pain represents a significant unmet medical need, affecting more than 400 million patients worldwide. HB-086 is a non-opioid compound with a unique mode of action, targeting the underlying cause in the peripheral nervous system to reverse neuropathic pain. A comprehensive preclinical data package demonstrated a fast onset and long-acting analgesic effect, and also the ability to prevent the development of neuropathic pain. The proceeds of the Series A first close will enable Hoba…
PR Newswire
11/12/2023

Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief…

Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial OfficerMassimiliano Colella joins as global Chief Commercial Officer leading CMR Surgical's commercial and marketing operations to bring Versius to more hospitals around the worldMassimiliano joins CMR at a time of continued expansion as the second largest soft tissue surgical robotics company, with more than 140 Versius installations and more than 15,000 surgical procedures...
Nasdaq GlobeNewswire
11/12/2023

Nyxoah Announces Real World Case Series Demonstrating Positive Results in…

Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®Data presented at the DGSM Conference in Berlin by Dr.Christian Plettenberg on December 8, 2023 Results showed an average AHI decrease of 73%Mont-Saint-Guibert, Belgium – December 11, 2023, 7:30am CET / 1:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of...
Nasdaq GlobeNewswire
11/12/2023

Groupe Casino: Communication by the Casino group

Communication by the Casino group Paris, 11 December 2023Following the press release issued yesterday by Companhia Brasileira De Distribuição (GPA), Casino group acknowledges that it is aware that GPA has initiated preliminary work efforts towards a potential primary equity offering as part of its plan to optimize its capital structure. GPA has convened an extraordinary general meeting on 11 January 2024 to deliberate on, among other matters, an increase in the Company's authorized...
Nasdaq GlobeNewswire
11/12/2023

Groupe Casino: Disposal of Casino stake in Éxito Group

Cession de la participation de Casino dans le groupe Éxito Paris, le 11 décembre 2023Suite à la précédente communication du 16 octobre 2023 relative à la cession par le groupe Casino de sa participation totale dans Almacenes Éxito S.A. (" Groupe Éxito ") à Grupo Calleja (" l'Acheteur "), le groupe Casino annonce que l'Acheteur a publié dans le journal colombien El Colombiano, le 10 décembre 2023, le premier avis de l'Offre Publique d'Achat qui sera lancée en Colombie (le…
Nasdaq GlobeNewswire
11/12/2023

Basilea announces that FDA approves expanded use of antifungal Cresemba®…

Allschwil, Switzerland, December 11, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its license partner Astellas Pharma US, Inc. (“Astellas”) received the approval of Cresemba ®(isavuconazole) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients by the US Food and Drug Administration...
Nasdaq GlobeNewswire
11/12/2023

Novartis investigational iptacopan Phase III study demonstrates clinically…

Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis 1 ; the safety profile of iptacopan was consistent with previously reported data 1-3 C3 glomerulopathy (C3G) is an ultra-rare complement-mediated kidney disease, with approximately 50% of patients progressing to kidney failure within 10 years of diagnosis 4-7 ; currently no treatments...
Nasdaq GlobeNewswire
11/12/2023

New data for Roche's Columvi and Lunsumio presented at ASH 2023 support…

Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas 1,2 New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies 3,4,5,6 Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody...
Nasdaq GlobeNewswire
11/12/2023

Deenova achieves unprecedented success with third consecutive sales record in…

In a key move towards internationalization,Deenovaentered the Nordics market by winningNorway'spublic tender. The company is set to deliver the unit dose repackaging machine toSjukehusapoteka Vest HFandSykehusapotekene HF, reinforcing its commitment to advancing healthcare automation in the region. Simultaneously,Deenovaachieved another significant win inMoroccoby securing the pharmacy automation service atCHU Benguerir, marking the first of its kind in the...
PR Newswire
11/12/2023

Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of…

Sarclisa ®(isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alonePhase 3 data showed Sarclisa added to carfilzomib, lenalidomide and dexamethasone (KRd) in patients with newly diagnosed, transplant-eligible multiple myeloma resulted in 77% of patients achieving minimal residual disease (MRD) negativity after consolidation therapy, detected with a sensitivity of 10...
Nasdaq GlobeNewswire
11/12/2023

Novartis presents new 48-week results from Phase III APPLY-PNH trial showing…

APPLY-PNH extension data show that continuous Fabhalta ®(iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigue in the majority of patients, with a safety profile consistent with previously reported data 1-5 Patients switching from anti-C5s to Fabhalta in the extension period achieved outcomes comparable to...
Nasdaq GlobeNewswire
11/12/2023

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of…

Part 5 data reinforces favorable safety and tolerability profile and long-term efficacy results for SerpinPC:Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline No thromboembolic events or treatment-related sustained elevations of D-dimer observedPoster presentation at American Society of Hematology (ASH) Annual meeting Registrational PRESent-2 and PRESent-3 studies of SerpinPC in hemophilia B are ongoing BOSTON and LONDON, Dec.10, 2023(GLOBE...
Nasdaq GlobeNewswire
10/12/2023

Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the manufacture…

The manufacturing of Clexane® will take place in Minapharm's second new state-of-the-art biopharmaceutical facility in Egypt dedicated to research, development and manufacture of complex bioengineered proteins. The manufacturing of Clexane® will take place in Minapharm's second new state-of-the-art biopharmaceutical facility inEgyptdedicated to research, development and manufacture of complex bioengineered proteins. In the presence of Sanofi Senior Management,Christelle Saghbini, Head...
PR Newswire
10/12/2023

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T…

Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstractsGalapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET;...
Nasdaq GlobeNewswire
09/12/2023

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20)…

Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65 thAmerican Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized...
Nasdaq GlobeNewswire
09/12/2023

New data reinforce the benefit of early preventative treatment with Roche's…

Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth1 At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma1 Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed1 The...
Nasdaq GlobeNewswire
09/12/2023
Altri  Comunicati